- Ongoing, recruitingTherapeutic use (Phase IV)
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS
This study looks at how long people with a certain type of pancreatic cancer live after receiving treatment. It specifically focuses on real-world experiences with common chemotherapy drugs before surgery.
For: Resectable pancreatic adenocarcinoma with risk factorsSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39)
This study looks at a new way to treat stomach and gullet cancer after surgery. Half of the patients get less chemotherapy, and the other half get the usual amount. We want to see if less treatment is just as good, safer, and helps people feel better.
For: Low risk of disease recurrence · defined by the following criteria: - Absence of lymph node involvement (ypN0) · assessed on a min. of 15 lymph nodes andFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study looks at a new drug, DKN-01, combined with standard treatments for advanced bowel cancer. It compares this new combination to the standard treatments alone, to see if it helps people live longer without their cancer growing.
For: Colorectal CancerGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
This study is looking at new ways to treat advanced oesophageal cancer. We're testing a combination of new drugs and chemotherapy to see if it works better than standard treatments, with a focus on safety and how long people live while on the treatment.
For: Esophageal CarcinomaSpain · Hungary · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a Multicenter, Randomized, Double Blind, Parallel-group, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Subjects with Active Rheumatoid Arthritis despite Prior Treatment with Advanced Therapies (bDMARD or tsDMARD)
This study is looking at a new combination of two medicines, nipocalimab and certolizumab (Cimzia), for adults with rheumatoid arthritis that hasn't improved with other strong treatments. We want to see if this combination helps reduce symptoms and is safe after 12 weeks.
For: Rheumatoid ArthritisGermany · Poland · Hungary - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
This study looks at new drug combinations for advanced stomach or food pipe cancer. It compares a new mix of drugs (Lenvatinib, Pembrolizumab, and chemotherapy) against the usual treatment to see which works best and is safest for patients.
For: Advanced/Metastatic Gastroesophageal AdenocarcinomaSpain · Belgium · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
For: Gastric and gastroesophageal junction (GEJ) adenocarcinomaPoland · Belgium · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
This study is testing a new combination of treatments for advanced pancreatic cancer that hasn't been treated with chemotherapy before. It compares a new drug mix (irinotecan liposome, oxaliplatin, 5-fluorouracil/leucovorin) against a standard treatment (nab-paclitaxel, gemcitabine) to see which helps people live longer.
For: Metastatic Pancreatic AdenocarcinomaSpain - AuthorisedTherapeutic confirmatory (Phase III)
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
This study is looking at different chemotherapy treatments for people in the UK who have had pancreatic cancer removed by surgery. It aims to find out which treatment works best to stop the cancer from coming back by comparing standard care with a new way of choosing treatment based on genetic information.
For: Resected pancreatic ductal adenocarcinomaGermany · Sweden - AuthorisedTherapeutic exploratory (Phase II)
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
This study is looking at a new way to treat locally advanced rectal cancer. It combines standard chemotherapy and radiotherapy with a new drug called Durvalumab to see if this combination causes the cancer to completely disappear before surgery.
For: Locally advanced rectal cancerSpain - AuthorisedTherapeutic exploratory (Phase II)
Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)
This study looks at different ways to give a common chemotherapy treatment (FOLFIRI) for advanced bowel cancer. Researchers want to see if giving it less often works just as well at keeping the cancer under control, while hopefully making treatment easier for patients.
For: Metastatic colorectal cancerHungary